I’m a bit late with this post as February’s PME (Pharmaceutical Market Europe) has been out for a while now. Once again the magazine features the latest print outing for my Digital Intelligence blog.
It asks, after the MHRA approves its first app, whether pharma mobile apps are medical devices. There’s also room for a look at the FDA’s ‘social media’ guidance on off-label information requests, a real-world evidence collaboration between AstraZeneca and IMS Health and much more.
• Read February’s PME in full online
